Institutional members access full text with Ovid®

Share this article on:

Vanishing Endometrial Carcinoma

Dubé, Valérie M.D.; Macdonald, Denis M.D.; Allingham-Hawkins, Diane J. Ph.D.; Kamel-Reid, Suzanne Ph.D.; Colgan, Terence J. M.D.

International Journal of Gynecological Pathology: July 2007 - Volume 26 - Issue 3 - pp 271-277
doi: 10.1097/01.pgp.0000236945.74711.ef
Pathology of the Corpus

Summary: Three cases of histologically proven endometrial carcinoma (EmCa) demonstrated no residual carcinoma or biopsy site on the subsequent hysterectomy specimen. The shared identity of both endometrial biopsy and hysterectomy specimen was proven, and specimen misidentification was excluded in all 3 cases through successful DNA profiling. Just as vanishing cancer in prostatic carcinoma has recently been defined and accepted, it is suggested that vanishing EmCa can also be defined using specific pathological and clinical criteria. DNA profiling may serve to confirm the diagnosis. Vanishing EmCa is only a small subset within hysterectomy specimens that show no EmCa after a histological diagnosis of EmCa. The concept of vanishing EmCa may be useful in both clinical and medicolegal practice.

From Department of Pathology, Mount Sinai Hospital (V.D., T.J.C.); Departments of Pathology (D.M.) and Genetics Program (D.J.A.H.), North York General Hospital; and Department of Pathology, Division of Molecular Diagnostics, Toronto Medical Laboratories/University Health Network (S.K.R.), Toronto, Ontario, Canada.

Address correspondence and reprint requests to Terence Colgan, M.D., Department of Pathology and Laboratory Medicine, Room 6-502-3, Mount Sinai Hospital, 600 University Avenue, Toronto, Ontario, Canada M5G 1X5. E-mail: tcolgan@mtsinai.on.ca.

©2007International Society of Gynecological Pathologists